Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16156822 | 0.92 | PSEN1 (0.38) | CHEK1TP53RAB9APSEN1PSEN2 | |
| SCHEMBL17482017 | 0.76 | PLK1 (0.31) | PLK1 | |
| SCHEMBL17482077 | 0.72 | PSEN1 (0.41) | CHEK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL17482016 | 0.72 | KCNK2 (0.57) | TP53MEN1HTTKMT2A | |
| SCHEMBL17482048 | 0.71 | KCNK2 (0.36) | — | |
| SCHEMBL17482043 | 0.71 | KCNK2 (0.36) | TP53 | |
| SCHEMBL17482056 | 0.71 | KCNK2 (0.47) | TP53MEN1KMT2A | |
| SCHEMBL17482063 | 0.71 | KCNK2 (0.47) | TP53PTGDR2MEN1KMT2A | |
| SCHEMBL17482067 | 0.70 | KCNK2 (0.47) | TP53MEN1KMT2A | |
| SCHEMBL17482004 | 0.70 | RAB9A (0.70) | CHEK1TP53RAB9APSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862684-B2 | Modulation of K2P channels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | KCNJ2, KCNK2, KCNN3 | CHEK1 2778/4885TP53 4555/4885RAB9A 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.